Independent Probe Flags Greatview Aseptic Flawed Accounting, Weak Controls

MT Newswires Live2025-10-03

Greatview Aseptic Packaging (HKG:0468) said an independent investigation found no sufficient basis for consolidating its international business following a 2024 restructuring and highlighted significant internal control weaknesses, according to a Thursday filing.

The probe by Grant Thornton also raised concerns over the carve-out of certain overseas units in transaction size tests, which may have been aimed at avoiding shareholder approval requirements.

It further cited inadequate disclosure of related-party transactions and undisclosed purchases of financial products, according to the filing.

The board accepted the findings, saying it will restate its 2024 financials, appoint an internal-control consultant, conduct a second-stage investigation, and pursue legal action to unwind parts of the restructuring.

Trading in Greatview shares, suspended since Feb. 19, remains halted until further notice.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment